332: Alemtuzumab (ALEM) and Continuous-Infusion Pentostatin (PENTO): A Novel Nonmyeloablative (NM) Preparative Regimen for Allogeneic (allo) Hematopoietic Cell Transplantation (HCT)  by Klinkhammer, T.A. et al.
122 Poster Session IIAnasetti, C.1. 1H. Lee Moffitt Cancer Center and University of South
Florida, Tampa, FL; 2H. Lee Moffitt Cancer Center and University of
South Florida, Tampa, FL.
There is limited data evaluating the feasibility of combining rit-
uximab with conditioning chemotherapy (or chemo-radiotherapy)
for patients undergoing allogeneic hematopoietic cell transplanta-
tion (allo-HCT). Twelve patients (M 5 7; F 5 5), with median
age of 54.5 (41–66) years, underwent allo-HCT for the following
diagnoses (disease-status at transplantation) [chronic lymphocytic
leukemia (CLL)5 7 (CR2 5 2; PR2 5 3; $PR3 5 2); mantle cell
lymphoma (MCL)5 3 (CR1 5 1; $PR2 5 2); follicular NHL 5 1
(CR3 5 1), diffuse large B-cell (DLBC) NHL 5 1 (.PR3 5 1)].
Donors were as follows: matched-related donors (MRD) 5 7;
matched-unrelated donors (MUD) 53; mismatched donor
(MMD)5 2. Fludarabine-based regimens comprised fludarabine
plus targeted doses of intravenous busulfan (FLU-BU 5 8), or to-
tal-body irradiation (FLU-TBI 5 3), or cyclophosphamide (FLU-
CY 5 1). Anti-thymocyte glogulin (ATG) was administered in
MMD cases. GVHD prophylaxis consisted of tacrolimus plus my-
cophenolate mofetil5 8, or methotrexate5 4. Nine (75%) patients
received rituximab 375 mg/m2 on days11 (63 days) and all (100%)
received rituximab 375 mg/m2 on day18 (63 days) without serious
infusion reactions. All patients engrafted. Median time to neutro-
phil engraftment for entire cohort was 15.5 (12–21) days. Median
time to platelet engraftment in 8 patients was 13.5 (10–18) days.
Four patients never dropped their platelet counts below 20,000/
uL. Median donor chimerism at day 190 (610 days) for unsorted
BM, CD3 and CD33 by PCR/STR were 95% (70–100%), 87.5%
(59–100%) and 100%, respectively. At a median follow-up of 6
(2.2–32) months, the 100-day non-relapse mortality in 11 evaluable
patients was 10%. Acute GVHD, grades II, III, IV, developed in
58%, 8.3% and 8.3%, respectively, at a median of 28 (16–77)
days. Response rates, at day1100 (610 days), according to diagno-
sis, in 10 evaluable patients were as follows: CLL (CR5 4/5; PR5
1/5); MCL: (CR5 3/3); follicular NHL (CR5 1/1); DLBC: (pro-
gressive disease 5 1/1). Administration of rituximab is feasible and
does not affect timely hematopoietic engraftment in allo-HCT re-
cipients with advanced CD201 malignancies.331
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Background: Peripheral blood hematopoietic stem cells (PBSC)
mobilized with granulocyte colony stimulating factor (G-CSF) are
increasingly used for hematopoietic rescue in transplant proce-
dures. G-CSF mobilization results in adequate PBSC collection
in most healthy donors after 1 or 2 apheresis procedures. However,
factors affecting mobilization have not been elucidated. A recent
study showed that smoking cessation was associated with a rapid in-
crease in circulating vascular endothelial progenitor cells (VEPC) in
peripheral blood. Hence, we evaluated the effect of smoking on
PBSC mobilization. Methods: All healthy donor PBSC collections
at our center were included. Data on donor age, sex, weight, G-CSF
dose and schedule, total CD341 cells collected and time to engraft-
ment, were reviewed. Data on smoking were categorized as current,
past and never smokers. Poor mobilization was defined as collection
of less than 2  106 CD341 cells/kg after a single apheresis proce-
dure processing 10 liters of blood.Results: 368 healthy donors were
included from 1993 to 2007. Of these, 192 (52%) never smoked, 92
(25%) were current smokers, 59 (16%) were past smokers and the
status of 25 (7%) was unknown. 122 (33%) healthy donors were
found to be poor mobilizers by our definition. Distribution of cur-
rent, past and never smokers was similar between good and poor
mobilizers (p 5 0.34). There was no significant difference between
poor mobilization and current, past or never smoking status.However, a small effect trending toward poorer mobilization
amongst current smokers (p 5 0.20) versus never/past smokers
and ever smokers (p 5 0.15) versus never smokers was identified.
Poor mobilization was related to delayed engraftment (p 5 0.03).
We failed to detect significant association between smoking history
and time to engraftment. Conclusions: Smoking seems to have
a small, if any, impact on mobilization of hematopoietic stem cells.
The lack of significant effect of smoking may be due to several rea-
sons:
- Effects of smoking may be more pronounced in the steady state.
- Stimulation by growth factors (G-CSF) may have blunted this ef-
fect.
- Effect of smoking on the stem cells and marrow stroma may be
more pronounced in diseased individuals (i.e. autologous donors).
This study was limited to healthy donors.
- Smoking may have a differential effect on VEPC versus hemato-
poietic stem cells.
Studies on PBSC mobilization in individuals undergoing autolo-
gous transplant may shed further light on this issue.332
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Current NM preparative regimens for allo HCT consistently
cause significant post-HCT neutropenia and thrombocytopenia.
To test the hypothesis that pre-HCT immunosuppression alone al-
lows engraftment without significant myelosuppression, we are
evaluating a preparative regimen of continuous-infusion PENTO
(12 mg/m2 over 72 hr, days -8 through -6) and ALEM (20 mg/
day, days -5 through -1) for allo HCT in high-risk patients (pts)
with hematologic malignancies. To date, 5 pts (median age, 64 yr;
range, 54–69 yr) with AML (3 pts), CLL (1 pt), or multiple myeloma
(MM) (1 pt) have been enrolled on this trial; 2 pts (1 AML, 1 MM)
had failed previous autologous HCT. The median interval between
most recent conventional chemotherapy (chemoRx) and allo HCT
was 3 (range, 2–5) mo. All pts received G-CSF mobilized PBSCs
from 8/8 HLA-matched unrelated donors; median cell doses were
2.86 (range, 1.86–6.0)  106 CD341 cells/kg and 3.33 (range,
1.57–4.46)  108 CD31 cells/kg. Cyclosporine (CSA) was used
for GVHD prophylaxis. All pts had asymptomatic transient eleva-
tions of AST and ALT (CTCAE grade 2–3) between days -6 and
-2. Median duration of hospitalization post-HCT was 6 (range,
3–62) days. The median nadir of absolute neutrophil count was
0.75 (range, 0.18–1.42)  109/L at a median of day 116 (range,
day 111-day 121), and the median nadir of platelet count was 46
(range, 18–183)  109/L at a median of day 16 (range, day 11-
day 119). In contrast, the nadir of absolute lymphocyte count
(ALC) was 0 in all pts at a median of day 12 (range, day 0-day
112); at day 128, the median ALC was only 0.096 (range, 0.055–
0.32)  109/L. One pt developed grade II acute GVHD at day
121. Two pts had asymptomatic CMV reactivation at days 15
and111, respectively. At day128, bone marrow chimerism studies
showed a median of 27% (range, 13–100%) donor DNA. At day
1100, 3 of 4 evaluable pts had 38%, 84% and 100% donor chime-
rism, respectively; the pt with 38% donor DNA had recurrent MM,
and upon cessation of CSA, donor chimerism increased to 64% by
day 1124. One pt had no donor engraftment at day 1100 and had
the longest interval (5 mo) between conventional chemoRx and allo
HCT. Four pts are alive at a median of 1591 days (range, 461-2561)
after HCT; one pt with AML relapsed and died of GVHD after
a second allo HCT. These encouraging results suggest that immu-
nosuppression with PENTO and ALEM is a novel NM HCT strat-
egy that allows donor cell engraftment without significant
myelosuppression.
